Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.

Dang Q, Chen L, Xu M, You X, Zhou H, Zhang Y, Shi W.

Cell Signal. 2019 Mar 14;59:76-84. doi: 10.1016/j.cellsig.2019.03.013. [Epub ahead of print] Erratum in: Cell Signal. 2019 Apr 10;:.

PMID:
30878517
2.

Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.

Yang L, Zhang S, George SK, Teng R, You X, Xu M, Liu H, Sun X, Amin HM, Shi W.

Oncotarget. 2015 Jun 20;6(17):14953-69.

3.

Corrigendum to <'The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis'> [Cellular Signalling 59 (2019) 76-84].

Dang Q, Chen L, Xu M, You X, Zhou H, Zhang Y, Shi W.

Cell Signal. 2019 Apr 10. pii: S0898-6568(19)30079-8. doi: 10.1016/j.cellsig.2019.04.003. [Epub ahead of print] No abstract available.

PMID:
30981601
4.

Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.

Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS.

Cancer Res Treat. 2018 Apr;50(2):599-613. doi: 10.4143/crt.2016.357. Epub 2017 Jun 19.

5.

Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.

Ito M, Zhao N, Zeng Z, Chang CC, Zu Y.

Cancer Gene Ther. 2010 Sep;17(9):633-44. doi: 10.1038/cgt.2010.20. Epub 2010 May 7.

6.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.

7.

The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.

Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.

Exp Hematol. 2006 Dec;34(12):1670-9.

PMID:
17157164
8.

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.

Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL.

Leukemia. 2009 Aug;23(8):1507-14. doi: 10.1038/leu.2009.41. Epub 2009 Mar 12.

PMID:
19282831
9.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’.

Oncotarget. 2016 Nov 29;7(48):79637-79653. doi: 10.18632/oncotarget.12876.

10.
11.

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L.

Oncotarget. 2016 Nov 8;7(45):72886-72897. doi: 10.18632/oncotarget.12128.

12.

Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.

Biskup E, Kamstrup MR, Manfé V, Gniadecki R.

Br J Dermatol. 2013 Mar;168(3):504-12. doi: 10.1111/bjd.12071.

PMID:
23445313
13.

Intrinsic apoptotic pathway in anaplastic large cell lymphoma.

Oyarzo MP, Drakos E, Atwell C, Amin HM, Medeiros LJ, Rassidakis GZ.

Hum Pathol. 2006 Jul;37(7):874-82. Epub 2006 May 26.

PMID:
16784988
14.

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group.

Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347. Epub 2014 Dec 23.

15.

Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.

Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M.

Leukemia. 2005 Nov;19(11):1977-84.

PMID:
16151469
16.

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.

Cancer Res. 2006 Jul 1;66(13):6589-97.

17.

Caspase-3 activation in systemic anaplastic large-cell lymphoma.

Drakos E, Rassidakis GZ, Lai R, Herling M, O'Connor SL, Schmitt-Graeff A, McDonnell TJ, Medeiros LJ.

Mod Pathol. 2004 Jan;17(1):109-16.

18.

STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.

Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, Kneteman NM, Lai R.

Blood. 2015 Jul 16;126(3):336-45. doi: 10.1182/blood-2014-10-603738. Epub 2015 Apr 28.

19.

The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.

Carnesecchi S, Rougemont AL, Doroshow JH, Nagy M, Mouche S, Gumy-Pause F, Szanto I.

Free Radic Biol Med. 2015 Jul;84:22-29. doi: 10.1016/j.freeradbiomed.2015.02.027. Epub 2015 Mar 19.

PMID:
25797883
20.

Anaplastic large cell lymphoma, ALK-negative.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15. doi: 10.1016/j.critrevonc.2012.06.004. Epub 2012 Jul 11. Review.

Supplemental Content

Support Center